Category Specific RSS

Satire

Advisor adamant that THIS latest round of funding is the one which will turn company around

Shareholders of Fat Cactus Limited are buoyed that the company is finally set for a turnaround in fortunes following the latest round of capital raisings. 

It’s been a tough journey for shareholders in the company which listed on the sharemarket five years ago and are yet to report a single profitable quarter, despite raising capital each year since listing, and convincing shareholders to buy more. 

Vern Laidhoff, the corporate advisor leading the capital raising, has encouraged shareholders to participate in the raise and is confident it will go a long way towards shareholder returns. 

“This money will be crucial in working capital because the Fat Cactus team is so close to a major breakthrough and this extra million dollars will be just be what they need to achieve it,” said Laidhoff. 

“Once they get the breakthrough, it’s going to mean the company has a growth opportunity in emerging markets and can build shareholder value.

“By participating at 1 cent per share, shareholders can reduce their average purchase price for their holdings, and gain international exposure within their portfolio because something big could be on the horizon with this blue sky opportunity.” 

Fat Cactus initially floated at $2.00 per share with management consistently paid their annual remuneration from funds raised for “working capital”. 

Elias Pivep

Failed stand-up comic who now gets his kicks from Simpsons business memes.

Recent Posts

AML3D announces stronger FY26, with positive EBITDA reported in the second half

Adelaide-based metal printing group books record $12.5 million revenue and a record $78 million sales…

3 days ago

Refurbished tech gives Harris Technology a second life

Harris Technology has found a higher-margin growth engine in an unlikely place: the market for…

4 days ago

Imagion Biosystems Advances MagSense® Phase 2 Trial

Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial…

1 week ago

Acrux-developed Menopause Hormone Therapy to enter Australian market

Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market…

3 months ago

Evion Expands Critical Minerals Push with Nevada Fluorspar Option

The race to secure Western-aligned critical minerals supply chains is accelerating as governments and industry…

4 months ago

Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone

Green360 Technologies (ASX:GT3) has taken a major step forward in the commercialisation of its low-carbon…

4 months ago